KCR has extended its service portfolio with Trial Execution Consulting to support clients in translating scientific objectives into operational activity. The new service, led by Anna Baran, chief medical officer, is primarily dedicated to biotechnology companies as well as small and medium pharma.

Company development, innovations and values were the main themes among many others discussed at the KCR Annual Development Meeting. The company leaders from different countries met to review the company strategy and talk about its further dynamic evolution.

Patients’ safety is a top concern in clinical trials. KCR bolsters its pharmacovigilance and safety reporting with Oracle Argus.

Kendall Square in Cambridge, MA, is a district with approx. one square mile. What makes is so attractive for hundreds of biotech companies? Recently, we also see more and more European pharma companies joining the Boston neighborhood. Find out why…

Meet our representatives at the following upcoming industry events and discuss how we can partner for your clinical trial project:

	4-7 September 2018 / BioTech Week / Boston, U.S. / Request a meeting
	27-29 November 2018 / Partnership in Clinical Trials 2018 / Barcelona, Spain / Request a meeting

KCR is a Contract Research Organization (CRO) providing clinical development solutions for the pharmaceutical, biotechnology and medical device industries. The company supports clients with full-service capabilities across three main services: Trial Execution (TE), Functional Service Provision (FS) and Trial Execution Consulting (TC) over a broad range of therapeutic areas. KCR operates across four main regions: North America (NA), Western Europe (WE), Central Europe (CE) and Eastern Europe (EE) with hubs located in Boston, US, Berlin, Germany, Warsaw, Poland and Kiev, Ukraine respectively. The company’s geographical set up suits perfectly to deliver optimized trial execution strategies for life-changing therapies.

For more information, visit www.kcrcro.com.